VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
COLL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
COLLCollegium Pharmaceutical, Inc.
$25.55$841M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCOLLFinancials

Collegium Pharmaceutical, Inc. (COLL) Income Statement

13Y historyFree accessUpdated daily

Revenue reached $216.3M in 2026Q3 with gross margin recovering to 58.0% and operating margin to 11.9%, yet net income swung from -$15.1M in 2026Q2 to $21.8M, suggesting earnings remain highly sensitive to quarterly swings.

Income StatementBalance SheetCash FlowRatios

COLL Income Statement

Annual statement

COLL Income Statement

Collegium Pharmaceutical, Inc. (COLL) annual income statement — 13-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Sales/Revenue815.19M780.57M631.45M566.77M463.93M276.87M310.02M296.7M280.41M28.48M1.71M000
Revenue Growth %7.68%23.62%11.41%22.17%67.56%-10.69%4.49%5.81%884.73%1564.29%----
Cost of Goods Sold333.85M317.31M254.1M240.6M254.44M126.25M130.18M193.66M165.68M2.6M213K171K00
COGS % of Revenue-40.65%40.24%42.45%54.85%45.6%41.99%65.27%59.08%9.11%12.45%---
Gross Profit481.33M463.26M377.34M326.17M209.49M150.62M179.84M103.04M114.74M25.88M1.5M-171K00
Gross Margin %59.05%59.35%59.76%57.55%45.15%54.4%58.01%34.73%40.92%90.89%87.55%---
Gross Profit Growth %-22.77%15.69%55.7%39.09%-16.25%74.53%-10.19%343.32%1627.7%976.02%---
Operating Expenses360.62M276.17M207.45M159.21M176.17M132.99M123.6M126.79M135.42M101.33M95.58M26.91M17.66M16.04M
OpEx % of Revenue-35.38%32.85%28.09%37.97%48.03%39.87%42.73%48.29%355.84%5586.21%---
Selling, General & Admin273.82M276.17M182.98M159.21M172.19M118.96M113.83M116.45M126.76M92.76M80.63M18.93M2.71M1.89M
SG&A % of Revenue-35.38%28.98%28.09%37.11%42.97%36.72%39.25%45.2%325.73%4712.57%---
Research & Development00003.98M9.45M9.77M10.34M8.66M8.57M14.95M7.97M14.96M14.16M
R&D % of Revenue----0.86%3.41%3.15%3.48%3.09%30.1%873.64%---
Other Operating Expenses2M024.47M004.58M0000-94K000
Operating Income120.71M187.08M169.9M166.96M33.32M17.63M56.23M-23.75M-20.68M-75.45M-94.08M-26.91M-17.66M-16.04M
Operating Margin %14.81%23.97%26.91%29.46%7.18%6.37%18.14%-8%-7.38%-264.95%-5498.66%---
Operating Income Growth %-10.12%1.76%401.1%89.01%-68.65%336.79%-14.81%72.58%19.81%-249.66%-52.32%-10.12%-
EBITDA302.01M413.16M339.06M316.22M172.26M86.55M117.78M-8.27M90.22M-74.85M-93.43M-26.74M-17.48M-15.87M
EBITDA Margin %37.05%52.93%53.69%55.79%37.13%31.26%37.99%-2.79%32.17%-262.86%-5460.37%---
EBITDA Growth %-21.5%21.86%7.22%83.57%99.04%-26.52%1525.07%-109.16%220.53%19.88%-249.44%-52.97%-10.11%-
D&A (Non-Cash Add-back)177.28M226.07M169.16M149.26M138.94M68.92M61.55M15.48M110.91M594K655K171K187K169K
EBIT204.27M174.93M172.54M159.07M34.37M17.64M56.46M-21.81M-19M-74.86M-94.08M-26.82M-17.66M-16.12M
Net Interest Income-151.43M-71.02M-60M-67.72M-62.17M-21M-28.65M1.03M-18.44M582K-94K000
Interest Income10.69M11.29M13.98M15.62M1.05M12K232K1.94M1.69M582K0000
Interest Expense162.12M82.31M73.97M83.34M63.21M21.01M28.88M909K20.13M094K439K252K76K
Other Income/Expense-78.56M-94.47M-71.33M-91.23M-62.17M-21M-28.65M1.03M-18.44M582K-94K-348K-252K-155K
Pretax Income42.15M92.62M98.57M75.73M-28.85M-3.37M27.58M-22.72M-39.13M-74.86M-94.18M-27.25M-17.92M-16.2M
Pretax Margin %5.17%11.87%15.61%13.36%-6.22%-1.22%8.9%-7.66%-13.95%-262.91%-5504.15%---
Income Tax3.98M29.75M29.38M27.58M-3.85M-74.89M830K00094K-91K079K
Effective Tax Rate %9.45%32.12%29.8%36.41%13.33%2219.65%3.01%0%0%0%-0.1%0.33%0%-0.49%
Net Income38.17M62.87M69.19M48.16M-25M71.52M26.75M-22.72M-39.13M-74.86M-94.18M-27.25M-17.92M-16.2M
Net Margin %4.68%8.05%10.96%8.5%-5.39%25.83%8.63%-7.66%-13.95%-262.91%-5504.15%---
Net Income Growth %-34.69%-9.13%43.68%292.6%-134.96%167.33%217.74%41.93%47.74%20.51%-245.54%-52.12%-10.62%-
Net Income (Continuing)38.17M62.87M69.19M48.16M-25M71.52M26.75M-22.72M-39.13M-74.86M-94.18M-27.25M-17.92M-16.2M
Discontinued Operations00000000000000
Minority Interest00000000000000
EPS (Diluted)0.981.731.861.29-0.741.860.76-0.24-1.19-2.47-3.88-2.01-2.40-2.17
EPS Growth %-37.64%-6.99%44.19%274.32%-139.78%144.74%416.67%79.83%51.82%36.34%-93.03%16.25%-10.6%-
EPS (Basic)-1.982.141.60-0.742.050.78-0.24-1.19-2.47-3.88-2.01-2.40-2.17
Diluted Shares Outstanding39.11M39.7M40.42M41.79M33.83M41.05M35.15M33.45M32.95M30.27M24.26M13.54M7.47M7.47M
Basic Shares Outstanding31.73M31.71M32.27M33.74M33.83M34.94M34.41M33.45M32.88M30.27M24.26M13.54M7.47M7.47M
Dividend Payout Ratio--------------

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetStrained
Cash FlowStable
Top Statement Risk

Leverage Constrains Revenue Shortfall Tolerance

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Growth Decelerates Toward Single Digits

According to reported quarterly figures, Collegium's revenue rose 3.3% year over year to $216.3M in 2026Q3, a sharp deceleration from the 31.4% growth reported in 2025Q3 and suggesting the earlier expansion is maturing.

The reported figures suggest growth has moved from a high-teens-to-thirties pace in 2024 and 2025 toward a low single-digit rate, with 2026Q2 revenue actually declining 7.5% in net income terms despite 6.3% top-line growth. The mix of volume and pricing behind this slowdown is not disclosed in the supplied data, so it is unclear whether ADHD franchise momentum is fading or simply normalizing. Investors should monitor whether sequential revenue gains resume, as a sustained low-single-digit trajectory would weaken the case that the company is in a durable growth phase.

Gross Margin Recovers but Stays Below Peers

Based on reported income statement figures, Collegium's gross margin reached 58.0% in 2026Q3, recovering from 55.2% in 2026Q2, yet still trailing the roughly 77% to 80% gross margins reported for peers Harmony Biosciences and Supernus.

The persistent gap with peers appears consistent with the royalty burden and gross-to-net adjustments embedded in the Nucynta and Xtampza ER economics, which structurally cap the margin ceiling. The recent recovery is encouraging but has not yet returned to the 62% to 63% levels seen in late 2024 and late 2025, suggesting mix or pricing pressure has not fully reversed. Without the breakdown of royalty tiers and rebate rates, the drivers of the swing cannot be confirmed, so the margin trend should be treated as directional.

Net Income Volatility Obscures Underlying Earnings

As reported in financial statements, Collegium posted net income of -$15.1M in 2026Q2 against $21.8M in 2026Q3, and EPS swung from a $0.07 low in 2025Q1 to $0.84 in 2025Q3, signaling earnings that are highly sensitive to quarterly accruals.

The wide range in net income relative to operating income suggests that below-the-line items, including amortization of acquired intangibles and tax provision effects from NOL utilization, are contributing materially to reported results. Stock-based compensation of roughly $10M to $14M per quarter is modest but still represents a recurring non-cash charge that should be considered when assessing cash earnings power. The recent EPS miss of $1.96 against a $1.98 consensus is marginal, but the pattern of quarterly swings argues against relying on any single period as a reliable run-rate.

Operating Leverage Reverses in Recent Quarters

Based on reported figures, Collegium's operating margin fell from 28.8% in 2025Q4 to 1.9% in 2026Q2 before recovering to 11.9% in 2026Q3, with SG&A of $106.6M in 2026Q2 outpacing revenue growth.

The reported SG&A trend indicates that the company's commercial cost base has not been scaling efficiently with revenue, which reverses the operating leverage seen in 2024 when operating margin reached 32.7%. The 2026Q3 recovery suggests cost discipline may be returning, but the margin remains well below prior-year levels and below the roughly 21% to 24% operating margins reported for peers. Investors should monitor whether SG&A growth can be held below revenue growth going forward.

Leverage Limits Room for Execution Errors

Based on reported figures, Collegium's debt-to-equity ratio of 3.12 and a net margin of 8.1% leave limited cushion if revenue growth stalls further or opioid-related production quotas tighten.

The reported leverage suggests balance sheet sensitivity is high, and a further EPS shortfall or guidance revision could pressure debt servicing capacity and reduce flexibility for acquisitions meant to diversify away from the opioid franchise. The combination of decelerating growth and volatile quarterly earnings may indicate that the market's valuation depends more heavily on sustained ADHD volume conversion than the current headline numbers alone can confirm. This analysis is inferential, and the supplied data does not disclose debt maturities or covenant terms that would determine the actual level of risk.

COLL — Frequently Asked Questions

Quick answers to the most common questions about buying COLL stock.

What was Collegium Pharmaceutical, Inc.'s (COLL) revenue in 2025?

For fiscal year 2025, Collegium Pharmaceutical, Inc. (COLL) reported total revenue of $780.6M.

Is Collegium Pharmaceutical, Inc. (COLL) profitable?

Collegium Pharmaceutical, Inc. (COLL) is profitable, generating $62.9M in net income for the fiscal year ending 2025 with a net profit margin of 8.1%.

What is Collegium Pharmaceutical, Inc.'s operating profit margin?

Collegium Pharmaceutical, Inc. (COLL) reported an operating income of $187.1M, resulting in an operating profit margin of 24.0%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Collegium Pharmaceutical, Inc.'s gross profit and gross margin?

Collegium Pharmaceutical, Inc. (COLL) generated $463.3M in gross profit for the year, representing a gross profit margin of 59.3%. This demonstrates the company's core pricing power and production efficiency.